About PathogenDX
PathogenDX is a company based in Tucson (United States) founded in 2014 by Eric Lachance and Michael Hogan. PathogenDX has raised $11.58 million across 5 funding rounds from investors including NIH, HHS and Entourage Effect Capital. The company has 31 employees as of December 31, 2021. PathogenDX offers products and services including D3 Array™, Octa™ AutoPrep Station, and Sero X Assay. PathogenDX operates in a competitive market with competitors including Inflammatix, Agendia, GenomeDx Biosciences, Akonni and KromaTiD, among others.
- Headquarter Tucson, United States
- Employees 31 as on 31 Dec, 2021
- Founders Eric Lachance, Michael Hogan
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Pathogendx, Inc
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$11.58 M (USD)
in 5 rounds
-
Latest Funding Round
Not available
-
Investors
NIH
& 7 more
-
Employee Count
31
as on Dec 31, 2021
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of PathogenDX
PathogenDX offers a comprehensive portfolio of products and services, including D3 Array™, Octa™ AutoPrep Station, and Sero X Assay.
Rapid multiplexed pathogen detection for clinical and food use
Automates lab workflows for cannabis pathogen testing
Detects Salmonella serotypes in food processing
People of PathogenDX
Unlock access to complete
Unlock access to complete
Funding Insights of PathogenDX
PathogenDX has successfully raised a total of $11.58M across 5 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in PathogenDX
PathogenDX has secured backing from 8 investors, including institutional and venture fund investors. Prominent investors backing the company include NIH, HHS and Entourage Effect Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investment firm focused on cannabis industry growth and leadership.
|
Locked | Locked | Locked | |
|
Investments are focused on the emerging global cannabis industry.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for PathogenDX
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by PathogenDX
Investment portfolio details for PathogenDX
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - PathogenDX
Detailed financials for PathogenDX
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Pathogendx Comparisons
Peer comparison for PathogenDX
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of PathogenDX
PathogenDX operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Inflammatix, Agendia, GenomeDx Biosciences, Akonni and KromaTiD, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Provider of diagnostic solutions for systemic infections
|
|
| Locked | Locked | Locked |
Genomic diagnostic products for cancer treatment are provided.
|
|
| Locked | Locked | Locked |
Genomic tests for urologic cancers are developed and commercialized.
|
|
| Locked | Locked | Locked |
Molecular diagnostics for complex infections are developed by Akonni.
|
|
| Locked | Locked | Locked |
Molecular and genetic tests for detecting disease-causing mutations are provided.
|
Detailed competitors of PathogenDX
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Pathogendx
Complete news archive for PathogenDX
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about PathogenDX
PathogenDX was founded in 2014 and raised its 1st funding round 2 years after it was founded.
PathogenDX is headquartered in Tucson, United States. It is registered at Tucson, Arizona, United States.
PathogenDX is a funded company, having raised a total of $11.58M across 5 funding rounds to date.
As of Dec 31, 2021, the latest employee count at PathogenDX is 31.
PathogenDX was founded in 2014 and is based in Tucson, United States. DNA-based testing kits for pathogen detection are offered by the company to the botanicals, food, and agriculture industries. Operations center on microbial testing services, including those for cannabis and botanical applications, with a focus on supporting safety and quality assessments in these sectors.
PathogenDX's top competitors include Inflammatix, Agendia and KromaTiD.
PathogenDX offers D3 Array™, Octa™ AutoPrep Station, and Sero X Assay.
PathogenDX has 8 investors. Key investors include NIH, HHS, Entourage Effect Capital, Altitude Investment Management, and Arcadian Investment Partners.